Support & Resources - Avmapki™ Fakzynja™ Co-Pack HCP

This site is intended for US healthcare professionals.

Full Prescribing Information | Patient Site | Connect With A Rep Email Sign Up

This site is intended for US healthcare professionals.

Full Prescribing Information Patient Site Connect With A Rep Email Sign Up
Illustration of two women walking together on a park path

Support and resources for healthcare providers and their patients

Verastem Cares™ logo

Verastem Cares™ is designed to support you and your patients in navigating access to 
Avmapki Fakzynja Co‑Pack throughout the patient journey.

Our dedicated team is ready to help. Call Verastem Cares™ today.

866-351-8372

8AM–8PM ET Monday – Friday

Insurance navigation

We help confirm patient-specific coverage and identify prior authorization requirements that will help facilitate your completion of any necessary prior authorization requests. We will support you as you navigate the prior authorization and appeals processes, as appropriate and if necessary.

Financial and patient assistance programs

We offer coverage support options to reduce patient out-of-pocket costs. If your patient faces insurance-related delays, we offer a Quick Start program for those not yet on therapy and a bridge solution for those already treated with Avmapki Fakzynja Co‑Pack. If your patient has inadequate or no coverage, they may qualify for our Patient Assistance Program.*

Logistics support

Our team coordinates with your office, insurance companies, and when appropriate, specialty pharmacies to ensure patients can access Avmapki Fakzynja Co‑Pack per your direction.

Educational resources

We direct patients to valuable resources to better understand Avmapki Fakzynja Co‑Pack.

*Verastem Copay Card Program is for eligible patients with commercial insurance. Eligibility requirements include US residency and enrollment in Verastem CaresTM. Additional eligibility requirements may apply.

Enrollment Form

Complete a form to enroll a new patient prescribed Avmapki Fakzynja Co-Pack into Verastem Cares.™

ENGLISH SPANISH

Fax completed forms to 866-351-0121.

Resources for healthcare providers

patient profile: first recurrence

Review a hypothetical profile of a woman who is experiencing her first recurrence of KRAS-mutated LGSOC.

DOWNLOAD >>

patient profile: second recurrence

Review a hypothetical profile of a woman who is experiencing her second recurrence of KRAS-mutated LGSOC.

DOWNLOAD >>

Ocular Assessment Guide

A tool to help understand required assessments and support your clinically related conversations with patients.

DOWNLOAD >>

What to Know Brochure

A concise clinical guide to use before and during clinical management of patients receiving treatment.

DOWNLOAD >>

Product OrDERING Fact Sheet

Details on how to order Avmapki Fakzynja Co‑Pack.

DOWNLOAD >>

Diagram showing RAS/RAF/MEK/ERK and FAK pathways

AVMAPKI FAKZYNJA CO-PACK MECHANISM OF ACTION

Gain a better understanding of the multiple targets in two different pathways involved in KRAS-mutated LGSOC inhibited by Avmapki Fakzynja Co‑Pack

Resources for your patients

Patient Brochure

A resource for patients who are considering or starting Avmapki Fakzynja Co‑Pack.

DOWNLOAD >>

Patient Dosing Calendar

A useful tool to help your patients keep track of their treatment.

DOWNLOAD >>

Treatment Expectations Brochure

A brochure that helps new patients prepare for their treatment journey with Avmapki Fakzynja Co‑Pack. 

DOWNLOAD >>

How to Take Avmapki FakzyNja Co‑Pack

A short video to help patients learn about the dosing schedule and recommendations. 

WATCH VIDEO >>

Understanding How Avmapki Fakzynja Co-pack Works as a Combination Treatment

A short video designed for patients to help them understand the mechanism of action.

WATCH VIDEO >>

SIDE EFFECTS INFORMATION CARD

Resource for patients to learn how healthcare providers may monitor for and manage possible side effects.

DOWNLOAD >>

INDICATION

Avmapki Fakzynja Co‑Pack is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Ocular Toxicities: Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold Avmapki Fakzynja Co‑Pack for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue Avmapki Fakzynja Co‑Pack for any grade 4 toxicity.
  • Serious Skin Toxicities: Skin toxicities, including photosensitivity and Severe Cutaneous Adverse Reactions (SCARs), occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue Avmapki Fakzynja Co‑Pack based on severity, tolerability and duration.
  • Hepatotoxicity: Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue Avmapki Fakzynja Co‑Pack based on severity and persistence of abnormality.
  • Rhabdomyolysis: Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue Avmapki Fakzynja Co‑Pack based on severity and duration of the adverse reaction.
  • Embryo-Fetal Toxicity: Avmapki Fakzynja Co‑Pack can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

  • The most common (≥ 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.

Drug Interactions

  • Strong and moderate CYP3A4 inhibitors: Avoid concomitant use with Avmapki Fakzynja Co‑Pack.
  • Strong and moderate CYP3A4 inducers: Avoid concomitant use with Avmapki Fakzynja Co‑Pack.
  • Warfarin: Avoid concomitant use of Avmapki Fakzynja Co‑Pack with warfarin and use an alternative to warfarin.
  • Gastric acid reducing agents: Avoid concomitant use of Avmapki Fakzynja Co‑Pack with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer Fakzynja 2 hours before or 2 hours after the administration of a locally acting antacid.

Use in Specific Populations

  • Lactation: Advise not to breastfeed.
  • Fertility: May impair fertility in males and females.

Click here for full Prescribing Information